Inhibition of the p53-MDM2 Interaction: Targeting a Protein-Protein Interface

Molecular Cancer Research

Volumn 2, Issue 1, 2004, Pages 20-28

  Chène, Patrick ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; CHLOROFUSIN; COMPOUND SYC 7; POLYCYCLIC HYDROCARBON; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DEATH; CELL NUCLEUS; GENE; GENE ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; MDM2 GENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; PROTO ONCOGENE; REVIEW; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0842325666     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Vousden, K. H. and Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2: 594-604, 2002.
2. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature, 2: 215-221, 1992.
3. Soussi, T., Dehouche, K., and Beroud, C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat., 2: 105-213, 2000.
4. Picksley, S. M. and Lane, D. P. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53. Bioessays, 2: 689-690, 1993.
5. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 2: 1126-1132, 1993.
6. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 2: 1237-1245, 1992.
7. Honda, R. and Yasuda, H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene, 2: 1473-1476, 2000.
8. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., and Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem., 2: 8945-8951, 2000.
9. Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J., 2: 554-564, 1998.
10. Momand, J., Jung, D., Wilczynski, S., and Niland, J. The MDM2 gene amplification database. Nucleic Acids Res., 2: 3453-3459, 1998.
11. Eymin, B., Gazzeri, S., Brambilla, C., and Brambilla, E. Mdm2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors. Oncogene, 2: 2750-2761, 2002.
12. Polsky, D., Bastian, B. C., Hazan, C., Melzer, K., Pack, J., Houghton, A., Busam, K., Cordon-Cardo, C., and Osam, I. hdm2 protein overexpression, but not amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res., 2: 7642-7646, 2001.
13. Wang, H., Zeng, X., Oliver, P., Le, L. P., Chen, J., Chen, L., Zhou, W., Agrawal, S., and Zhang, R. MDM2 oncogene as a target for cancer therapy: an antisense approach. Int. J. Oncol., 2: 653-660, 1999.
14. Lai, Z., Yang, T., Kin, Y. B., Sielecki, T. M., Diamond, M. A., Strack, P., Rolfe, M., Caligiuri, M., Benfield, P. A., Auger, K. R., and Copeland, R. A. Differentiation of hdm2-mediated p53 ubiquitination and hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. USA, 2: 14734-14739, 2002.
15. Midgley, C. A., Desterro, J. M., Saville, M. K., Howard, S., Sparks, A., Hay, R. T., and Lane, D. P. An N-terminal p14ARF peptide blocks mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene, 2: 2312-2323, 2000.
16. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprotein mdm2 conceals the activation domain of tumor suppressor p53. Nature, 2: 857-860, 1993.
17. Chen, J., Marechal, V., and Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 2: 4107-4114, 1993.
18. Lin, J., Chen, J., Elenbaas, B., and Levine, A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 EIB 55-kD protein. Genes Dev., 2: 1235-1246, 1994.
19. Picksley, S. M., Vojtesek, B., Sparks, A., and Lane, D. P. Immunochemical analysis of the interaction of p53 with mdm2-fine mapping of the mdm2 binding site on p53 using synthetic peptides. Oncogene, 2: 2523-2529, 1994.
20. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. Structure of the mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 2: 948-953, 1996.
21. Schon, O., Friedler, A., Bycroft, M., Freund, S. M. V., and Fersht, A. R. Molecular mechanism of the interaction between mdm2 and p53. J. Mol. Biol., 2: 491-501, 2002.
22. Lai, Z., Auger, K. R., Manubay, C. M., and Copeland, R. A. Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. Arch. Biochem. Biophys., 2: 278-284, 2000.
23. Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., and Appella, E. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on mdm2 binding. J. Biol. Chem., 2: 9278-9283, 2000.
24. Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Muhlhahn, P., Schumacher, R., Hesse, F., Kaluza, B., Voelter, W., Engh, R. A., and Holak, T. A. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry, 2: 336-344, 2001.
25. Blommers, M. J. J., Fendrich, G., Garcia-Echeverria, C., and Chene, P. On the interaction between p53 and mdm2: transfer NOE study of p53-derived peptide ligated to mdm2. J. Am. Chem. Soc., 2: 3425-3426, 1997.
26. Uesugi, M. and Verdine, G. L. The a-helical FXXFF motif in p53: TAF interaction and discrimination by mdm2. Proc. Natl. Acad. Sci. USA, 2: 14801-14806, 1999.
27. Botuyan, M. V. E., Momand, J., and Chen, Y. Solution conformation of an essential region of the p53 transactivation domain. Fold Des., 2: 331-342, 1997.
28. Serrano, L. and Fersht, A. R. Capping and α-helix stability. Nature, 2: 296-299, 1989.
29. Massova, I. and Kollman, P. A. Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J. Am. Chem. Soc., 2: 8133-8143, 1999.
30. Chou, P. Y. and Fasman, G. D. Empirical predictions of protein conformation. Annu. Rev. Biochem., 2: 251-276, 1978.
31. McCoy, M. A., Gesell, J. J., Senior, M. M., and Wyss, D. F. Flexible lid to the p53-binding domain of human mdm2: implications for p53 regulation. Proc. Natl. Acad. Sci. USA, 2: 1645-1648, 2003.
32. Laskowski, R. A. SURFNET: a program for visualizing molecular surfaces, cavities and intramolecular interactions. J. Mol. Graph., 2: 323-330, 1995.
33. Jones, S. and Thornton, J. M. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. USA, 2: 13-20, 1996.
34. Bottger, V., Bottger, A., Howard, S. F., Picksley, S. M., Chene, P., Garcia-Echeverria, C., Hochkeppel, H. K., and Lane, D. P. Identification of novel mdm2 binding peptides by phage display. Oncogene, 2: 2141-2147, 1996.
35. Zhao, J., Wang, M., Chen, J., Luo, A., Wang, X., Wu, M., Yin, D., and Liu, Z. The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett., 2: 69-77, 2002.
36. Duncan, S. J., Gruschow, S., Williams, D. H., McNicholas, C., Purewal, R., Hajek, M., Gerlitz, M., Martin, S., Wrigley, S. K., and Moore, M. Isolation and structure elucidation of chlorofusin, a novel p53-mdm2 antagonist from a Fusarium sp. J. Am. Chem. Soc., 2: 554-560, 2001.
37. Duncan, S. J., Cooper, M. A., and Williams, D. H. Binding of an inhibitor of the p53/mdm2 interaction to mdm2. Chem. Commun., 316-317, 2003.
38. Bottger, A., Bottger, V., Garcia-Echeverria, C., Chene, P., Hochkeppel, H. K., Sampson, W., Ang, K., Howard, S. F., Picksley, S. M., and Lane, D. P. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol., 2: 744-756, 1997.
39. Garcia-Echeverria, C., Chene, P., Blommers, M. J., and Furet, P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem., 2: 3205-3208, 2000.
40. Banerjee, R., Basu, G., Chene, P., and Roy, S. Aib-based peptide backbone as scaffolds for helical peptide mimics. J. Peptide Res., 2: 88-94, 2002.
41. Marshall, G. R., Hodgkin, E. E., Langs, D. A., Smith, G. D., Zabrocki, J., and Leplawy, M. T. Factors governing helical preference of peptides containing multiple α,α-dialkyl amino acids. Proc. Natl. Acad. Sci. USA, 2: 487-491, 1990.
42. 3c homooligopeptides. Biopolymers, 2: 175-184, 1989.
43. Galatin, P. S. and Abraham, D. J. QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction. Proteins, 2: 169-175, 2001.
44. Bottger, A., Bottger, V., Sparks, A., Liu, W. L., Howard, S. F., and Lane, D. P. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol., 2: 860-869, 1997.
45. Wasylyk, C., Salvi, R., Argentini, M., Dureuil, C., Delumeau, I., Abecassis, J., Debussche, L., and Wasylyk, B. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene, 2: 1921-1934, 1999.
46. Chene, P., Fuchs, J., Bohn, J., Garcia-Echeverria, C., Furet, P., and Fabbro, D. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumor cell lines. J. Mol. Biol., 2: 245-253, 2000.
47. Chene, P., Fuchs, J., Carena, I., P., F., and Garcia Echeverria, C. Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett., 2: 293-297, 2002.
48. Harbour, J. W., Worley, L., Ma, D., and Cohen, M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol., 2: 1341-1346, 2002.
49. Shvarts, A., Steegenga, W. T., Riteco, N., Van Laar, T., Dekker. P., Bazuine, M., Van Ham, R. C. A., Van der Houven van Oordt, W., Hateboer, G., Van der Eb, A. J., and Jochemsen, A. G. Mdmx: a novel p53-binding protein with some functional properties of mdm2. EMBO J., 2: 5349-5357, 1996.
50. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J. C., Valent, A., Minty, A., Chalon, P., Lelias, J. M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 2: 809-819, 1997.
51. Yang, A., Kaghad, M., Wang, Y., Gilleett, E., Fleming, M. D., Dotsch, V., Andrews, N. C., Caput, D., and McKeon, F. p63, a p53 homologue at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell, 2: 305-316, 1998.
52. Michael, D. and Oren, M. The p53 and mdm2 families. Curr. Opin. Mol. Cell. Biol., 2: 53-59, 2002.
53. Marin, C. and Kaelin, W. G. p63 and p73: old members of a new family. Biochim. Biophys. Acta, 2: M93-M100, 2000.
54. Bottger, V., Bottger, A., Garcia-Echeverria, C., Ramos, Y. F., van der Eb, A. J., Jochemsen, A. G., and Lane, D. P. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene, 2 189-199, 1999.
55. Ongkeko, W. M., Wang, X. Q., Siu, W. Y., Lau, A. W., Yamashita, K., Harris, A. L., Cox, L. S., and Poon, R. Y. Mdm2 and mdmx bind and stabilize the p53-related protein p73. Curr. Biol., 2: 829-832, 1999.
56. Kadakia, M., Slader, C., and Berberich, S. J. Regulation of p63 function by mdm2 and mdmx. DNA Cell Biol., 2: 321-330, 2001.
57. Kane, S. A., Flecner, C. A., Zhang, Y. S., Davis, L. J., Musselman, A. L., and Huang, P. S. Development of binding assay for p53/hdm2 by using homogeneous time-resolved fluorescence. Anal. Biochem., 2: 29-38, 2000.
58. Chene, P. p53 as a target in cancer therapy. Exp. Opin. Ther. Patents, 2: 923-935, 2001.
59. Pellecchia, M., Sem, D. S., and Wuthrich, K. NMR in drug discovery. Nat. Rev. Drug Discov., 2: 211-219, 2002.